PhotoCure: Presentation Of The First Quarter 2017 Results And The Results From The Blue Light Flexible Cystoscopy With Hexvix/Cysview Phase III Study

Photocure will present its first quarter report on Tuesday 23 May 2017 at Hotel Continental, Oslo, Norway.

Additionally, Dr. Daneshmand will present the new phase 3 study results with Blue Light Flexible Cystoscopy (BLFCTM) with Hexvix®/Cysview® which recently was presented at the 2017 American Urological Association (AUA) annual meeting.

  • 08:00 - 08:35 Q1 presentation by Kjetil Hestdal, President and CEO, and Erik Dahl, CFO.
    The presentation will be held in Norwegian.
  • 08:35 - 08:40 Break
  • 08:40 - 09:00 Dr. Sia Daneshmand, MD, Associate Professor of Urology (Clinical Scholar); Director of Urologic Oncology, Director of Clinical Research and Urologic Oncology Fellowship Director at the University of Southern California, Los Angeles, USA.
    The presentation will be held in English.

The presentation will be publicly available at www.photocure.com. It will be possible to follow the presentation through http://webtv.hegnar.no/presentation.php?webcastId=52727534.

A light snack will be served from 07:30 (CET). The presentation is scheduled to conclude at 09:00 (CET).

Photocure will additionally host an audio webcast and conference call (http://webtv.hegnar.no/presentation.php?webcastId=52727745) the same day in English at 17:00 CET / 16:00 GMT / 11:00 EST.
Please join the event conference 5-10 minutes prior to the start time using the number and confirmation code below:

  • NORWAY: +47 2350 0296
  • UK: +44(0)330 336 9411
  • USA: +1 719 325 4746

Confirmation code: 1958114
It is possible to listen to a replay of the conference call on the following numbers:

  • NORWAY +47 2350 0077
  • UK +44 (0)207 984 7568
  • USA +1 719 457 0820

Confirmation code: 1958114

Please register your attendance to the breakfast presentation at Photocure by Monday 22 May.
Contact person: Grete Faye-Schjøll (e-mail: gfs@photocure.no / phone +47 22 06 22 10 / fax +47 22 06 22 18).

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

MORE ON THIS TOPIC